Cargando…

SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling

SU5416 plus chronic hypoxia causes pulmonary arterial hypertension in rats and is assumed to occur through VEGFR2 inhibition. Cabozantinib is a far more potent VEGFR2 inhibitor than SU5416. Therefore, we hypothesized that cabozantinib plus hypoxia would induce severe pulmonary arterial hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sitapara, Ravikumar, Sugarragchaa, Chuluunbaatar, Zisman, Lawrence S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202272/ https://www.ncbi.nlm.nih.gov/pubmed/34178306 http://dx.doi.org/10.1177/20458940211021528

Ejemplares similares

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
por: Sanada, Takayuki J., et al.
Publicado: (2020)

Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
por: Alencar, Allan K. N., et al.
Publicado: (2018)

Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition
por: Yu, Min, et al.
Publicado: (2020)

The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats
por: Shoji, Hiroki, et al.
Publicado: (2021)

Partially hydrolyzed guar gum suppresses the progression of pulmonary arterial hypertension in a SU5416/hypoxia rat model
por: Sanada, Takayuki J., et al.
Publicado: (2023)

SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model
por: Peloquin, Grace L., et al.
Publicado: (2019)

Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells
por: Liu, Ping, et al.
Publicado: (2021)

Upregulation of Aquaporin 1 Mediates Increased Migration and Proliferation in Pulmonary Vascular Cells From the Rat SU5416/Hypoxia Model of Pulmonary Hypertension
por: Yun, Xin, et al.
Publicado: (2021)

The selective PGI(2) receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats
por: Honda, Yohei, et al.
Publicado: (2020)

Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats
por: Zungu-Edmondson, Makhosazane, et al.
Publicado: (2017)

Effects of the vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor SU5416 on in vitro cultures of Plasmodium falciparum
por: Hempel, Casper, et al.
Publicado: (2014)

Echocardiographic evaluation of right heart failure which might be associated with DNA damage response in SU5416-hypoxia induced pulmonary hypertension rat model
por: Kuang, Meidan, et al.
Publicado: (2023)

Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension
por: Sitapara, Ravikumar, et al.
Publicado: (2021)

Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension
por: Pullamsetti, Soni Savai, et al.
Publicado: (2023)

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Shunt-type plexiform lesions identified in the Sugen5416/hypoxia rat model of pulmonary arterial hypertension using synchrotron-based phase-contrast micro-CT
por: van der Have, Oscar, et al.
Publicado: (2022)

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
por: Morales-Cano, Daniel, et al.
Publicado: (2023)

Human Umbilical Cord-Derived Mesenchymal Stem Cells Repair SU5416-Injured Emphysema by Inhibiting Apoptosis via Rescuing VEGF-VEGFR2-AKT Pathway in Rats
por: Chen, Qin, et al.
Publicado: (2022)

Response to: Are endothelial cell proliferation and mesenchymal transition as distinguishing characteristics of 3-week Sugen5416/hypoxia mice model?
por: Rodor, Julie, et al.
Publicado: (2023)

BMPR2 spruces up the endothelium in pulmonary hypertension
por: Xiong, Jianhua
Publicado: (2015)

Hypoxia‐induced pulmonary hypertension upregulates eNOS and TGF‐β contributing to sex‐linked differences in BMPR2 ( +/R899X ) mutant mice
por: Erewele, Ejehi O., et al.
Publicado: (2022)

The genetics of pulmonary arterial hypertension in the post-BMPR2 era
por: Fessel, Joshua P., et al.
Publicado: (2011)

Linking tumor hypoxia with VEGFR2 signaling and compensatory angiogenesis: Glycans make the difference
por: Croci, Diego O, et al.
Publicado: (2014)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension
por: Pousada, Guillermo, et al.
Publicado: (2017)

Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2
por: Novoyatleva, Tatyana, et al.
Publicado: (2021)

SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation
por: Mezrich, Joshua D., et al.
Publicado: (2012)

SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration
por: Thill, Michelle, et al.
Publicado: (2011)

SU5416 attenuated lipopolysaccharide-induced acute lung injury in mice by modulating properties of vascular endothelial cells
por: Huang, Xuqing, et al.
Publicado: (2019)

Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension
por: Johnson, Jennifer A, et al.
Publicado: (2009)

A Novel BMPR2 Mutation Associated with Pulmonary Arterial Hypertension in an Octogenarian
por: Johri, Shilpa, et al.
Publicado: (2010)

Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension
por: Hara, Hironori, et al.
Publicado: (2017)

15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation
por: Ahn, Kyung Jin, et al.
Publicado: (2019)

Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension
por: West, James, et al.
Publicado: (2020)

Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation
por: Montani, David, et al.
Publicado: (2021)

Influence of 2‐Methoxyestradiol and Sex on Hypoxia‐Induced Pulmonary Hypertension and Hypoxia‐Inducible Factor‐1‐α
por: Docherty, Craig K., et al.
Publicado: (2019)

Consequences of BMPR2 Deficiency in the Pulmonary Vasculature and Beyond: Contributions to Pulmonary Arterial Hypertension
por: Andruska, Adam, et al.
Publicado: (2018)

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
por: Tran, Benjamin Duy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_97eqo4prejopklkmgl3pdmhvg3